![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Teva Announces U.S. Availability of Zecuity Migraine Patch System
Teva Announces U.S. Availability of Zecuity Migraine Patch System
Teva Pharmaceutical Industries Ltd. Has announced the U.S. availability of Zecuity, a patch system designed to provide relief from migraine.
The single-use device, which delivers sumatriptan through the skin, is designed to be worn for a four-hour period either on the upper arm or thigh.
A clinical study of the device found that 18 percent of those using Zecuity experienced no headache pain after two hours of its application, versus only 9 percent of those using a non-medicated patch system, according to the company.
Zecuity is available by prescription through specialty pharmacies in the U.S. — Michael Cipriano
Upcoming Events
-
21Oct